Founded in 1984, Bain Capital is an alternative investment firm. They manage $105 billion in assets across their eighteen global locations. Their Bain Capital Life Sciences is a venture capital fund which specializes in buyouts, inflection capital, growth capital, turnaround and private equity investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and life science technology sectors.
Bain Capital Life Science was initially raised in May 2017 at $720 million.
Bain Capital Life Sciences has invested in Annexon Biosciences, Aptinyx, Arcutis Biotherapeutics, Cerevel Therapeuticvs, Constellation Pharmaceuticals, Dicerna Pharmaceuticals Inc., Gynesonics, Hugel, InlfaRx, Kestra Medical Technologies, Marinus Pharmaceuticals, Rapid Micro Biosystems, Replimune, SpringWorks Therapeutics, Solid Biosciences and ViaCyte.
Bain Capital Life Sciences has exited their investments in SpringWorks Therapeutics, Dicerna Pharmaceuticals, Solid Biosciences, Aptinyx, Replimune Group, and InflaRx.
Documentaries, videos and podcasts